Global Erythropoietin Epo Drugs Market

Erythropoietin Epo Drugs Comprehensive Study by Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), Application (Cancer, Hematology, Renal diseases, Neurology), Drug Class (Biologics, Biosimilars) Players and Region - Global Market Outlook to 2027

Erythropoietin Epo Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Erythropoietin Epo Drugs?
Erythropoietin EPO Drugs is a glycoprotein cytokine secreted primarily by the kidneys in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (approximately 10 mU/mL) are continuously secreted in sufficient quantities to compensate for normal red blood cell turnover. Any anemia and hypoxemia due to chronic lung disease are common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10,000 mU/mL). Erythropoietin is produced in the kidney by interstitial fibroblasts near the peritubular capillary and proximal convoluted tubule. It is also produced in liver per sinusoidal cells.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledJohnson & Johnson (United States), Celltrion, Inc. (South Korea), Teva Pharmaceutical Industries Ltd. (Israel), Amgen Inc. (United States), Roche Holding AG (Switzerland), LG Life Sciences Ltd. (South Korea), Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India) and Dr. Reddy's Laboratories Ltd. (India)


The study covers a detailed analysis segmented by key business segments i.e. by type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Others) , by application (Cancer, Hematology, Renal diseases and Neurology) and major geographies. Research Analyst at AMA predicts that Indians Players will contribute to the maximum growth of Global Erythropoietin Epo Drugs market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Erythropoietin Epo Drugs market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Johnson & Johnson (United States), Celltrion, Inc. (South Korea), Teva Pharmaceutical Industries Ltd. (Israel), Amgen Inc. (United States), Roche Holding AG (Switzerland), LG Life Sciences Ltd. (South Korea), Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India) and Dr. Reddy's Laboratories Ltd. (India).

Market Overview:
On 30th November 2020, Celltrion has completed the acquisition of select primary care assets in the Asia Pacific from Takeda Pharmaceutical Company Limited, launching efforts to strengthen its R&D capability in the global small molecule pharmaceuticals business.
We hypothesize that EPO will affect all three major levels of respiratory function in COVID-19 patients. Brainstem centers and the phrenic nerve may benefit from EPO's nervous system effects, which may contribute to improved respiration. EPO, for example, attenuates the ventilatory response to CO2 in rats, i.e., it tunes the hypercapnia-induced hyperpnoea. MEK1/2 and PI3K are involved in EPO-mediated regulation of the central respiratory command. These pathways are also required for phrenic motor facilitation induced by cervical spinal EPO, indicating that it induces spinal plasticity in respiratory motor control under prolonged or recurring low oxygen conditions.
As preferred strategies, the companies are exploring the market through expansions, investments, new service launches, and collaborations. To gain a competitive advantage through collaborative efforts, the players are expanding and acquiring new geographies around the world.

Erythropoietin Epo Drugs Market Dynamics:
AttributesDetails
Growth Drivers
  • Cases of Cancer, HIV, Kidney Disease, and Anaemia Are On the Rise
  • Rising Public Awareness of the Advantages of EPO Therapeutics
Major Trends
  • Erythropoietin Biosimilars Are Becoming More Commercially Viable
Restraints
  • High Cost of the Erythropoietin Epo Drugs
  • Adverse Amount of Side Effects
Road Blocks / Challenges
  • Treatments will last longer
Gaps & Opportunities
  • Commercialization of Darbepoetin Alfa Biosimilar
  • Achieving Economies of Scale across Developed Region with Biosimilar Version of EPO


Key highlights of the Global Erythropoietin Epo Drugs market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Erythropoietin Epo Drugs market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Erythropoietin Epo Drugs market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Erythropoietin Epo Drugs Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Erythropoietin Epo Drugs market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Erythropoietin Epo Drugs market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Pharmaceutical companies, Research and Development (R&D) Companies, Government and Independent Research Laboratories, Contract Research Organizations (CROs), Medical Research Laboratories, Academic Medical Institutes and Universities, Government Bodies, End-Users and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Others
By Application
  • Cancer
  • Hematology
  • Renal diseases
  • Neurology
By Drug Class
  • Biologics
  • Biosimilars

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Cases of Cancer, HIV, Kidney Disease, and Anaemia Are On the Rise
      • 3.2.2. Rising Public Awareness of the Advantages of EPO Therapeutics
    • 3.3. Market Challenges
      • 3.3.1. Treatments will last longer
    • 3.4. Market Trends
      • 3.4.1. Erythropoietin Biosimilars Are Becoming More Commercially Viable
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Erythropoietin Epo Drugs, by Type, Application, Drug Class and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Erythropoietin Epo Drugs (Value)
      • 5.2.1. Global Erythropoietin Epo Drugs by: Type (Value)
        • 5.2.1.1. Epoetin-alfa
        • 5.2.1.2. Epoetin-beta
        • 5.2.1.3. Darbepoetin-alfa
        • 5.2.1.4. Others
      • 5.2.2. Global Erythropoietin Epo Drugs by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Hematology
        • 5.2.2.3. Renal diseases
        • 5.2.2.4. Neurology
      • 5.2.3. Global Erythropoietin Epo Drugs by: Drug Class (Value)
        • 5.2.3.1. Biologics
        • 5.2.3.2. Biosimilars
      • 5.2.4. Global Erythropoietin Epo Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Erythropoietin Epo Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Celltrion, Inc. (South Korea)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche Holding AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LG Life Sciences Ltd. (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biocon Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Intas Pharmaceuticals Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Dr. Reddy's Laboratories Ltd. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Erythropoietin Epo Drugs Sale, by Type, Application, Drug Class and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Erythropoietin Epo Drugs (Value)
      • 7.2.1. Global Erythropoietin Epo Drugs by: Type (Value)
        • 7.2.1.1. Epoetin-alfa
        • 7.2.1.2. Epoetin-beta
        • 7.2.1.3. Darbepoetin-alfa
        • 7.2.1.4. Others
      • 7.2.2. Global Erythropoietin Epo Drugs by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Hematology
        • 7.2.2.3. Renal diseases
        • 7.2.2.4. Neurology
      • 7.2.3. Global Erythropoietin Epo Drugs by: Drug Class (Value)
        • 7.2.3.1. Biologics
        • 7.2.3.2. Biosimilars
      • 7.2.4. Global Erythropoietin Epo Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Erythropoietin Epo Drugs: by Type(USD Million)
  • Table 2. Erythropoietin Epo Drugs Epoetin-alfa , by Region USD Million (2016-2021)
  • Table 3. Erythropoietin Epo Drugs Epoetin-beta , by Region USD Million (2016-2021)
  • Table 4. Erythropoietin Epo Drugs Darbepoetin-alfa , by Region USD Million (2016-2021)
  • Table 5. Erythropoietin Epo Drugs Others , by Region USD Million (2016-2021)
  • Table 6. Erythropoietin Epo Drugs: by Application(USD Million)
  • Table 7. Erythropoietin Epo Drugs Cancer , by Region USD Million (2016-2021)
  • Table 8. Erythropoietin Epo Drugs Hematology , by Region USD Million (2016-2021)
  • Table 9. Erythropoietin Epo Drugs Renal diseases , by Region USD Million (2016-2021)
  • Table 10. Erythropoietin Epo Drugs Neurology , by Region USD Million (2016-2021)
  • Table 11. Erythropoietin Epo Drugs: by Drug Class(USD Million)
  • Table 12. Erythropoietin Epo Drugs Biologics , by Region USD Million (2016-2021)
  • Table 13. Erythropoietin Epo Drugs Biosimilars , by Region USD Million (2016-2021)
  • Table 14. South America Erythropoietin Epo Drugs, by Country USD Million (2016-2021)
  • Table 15. South America Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 16. South America Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 17. South America Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 18. Brazil Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 19. Brazil Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 20. Brazil Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 21. Argentina Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 22. Argentina Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 23. Argentina Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 24. Rest of South America Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 25. Rest of South America Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 26. Rest of South America Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 27. Asia Pacific Erythropoietin Epo Drugs, by Country USD Million (2016-2021)
  • Table 28. Asia Pacific Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 29. Asia Pacific Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 30. Asia Pacific Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 31. China Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 32. China Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 33. China Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 34. Japan Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 35. Japan Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 36. Japan Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 37. India Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 38. India Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 39. India Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 40. South Korea Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 41. South Korea Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 42. South Korea Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 43. Australia Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 44. Australia Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 45. Australia Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 49. Europe Erythropoietin Epo Drugs, by Country USD Million (2016-2021)
  • Table 50. Europe Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 51. Europe Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 52. Europe Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 53. Germany Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 54. Germany Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 55. Germany Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 56. France Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 57. France Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 58. France Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 59. Italy Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 60. Italy Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 61. Italy Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 62. United Kingdom Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 63. United Kingdom Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 64. United Kingdom Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 65. Netherlands Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 66. Netherlands Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 67. Netherlands Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 68. Rest of Europe Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 69. Rest of Europe Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 70. Rest of Europe Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 71. MEA Erythropoietin Epo Drugs, by Country USD Million (2016-2021)
  • Table 72. MEA Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 73. MEA Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 74. MEA Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 75. Middle East Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 76. Middle East Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 77. Middle East Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 78. Africa Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 79. Africa Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 80. Africa Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 81. North America Erythropoietin Epo Drugs, by Country USD Million (2016-2021)
  • Table 82. North America Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 83. North America Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 84. North America Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 85. United States Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 86. United States Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 87. United States Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 88. Canada Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 89. Canada Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 90. Canada Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 91. Mexico Erythropoietin Epo Drugs, by Type USD Million (2016-2021)
  • Table 92. Mexico Erythropoietin Epo Drugs, by Application USD Million (2016-2021)
  • Table 93. Mexico Erythropoietin Epo Drugs, by Drug Class USD Million (2016-2021)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Erythropoietin Epo Drugs: by Type(USD Million)
  • Table 105. Erythropoietin Epo Drugs Epoetin-alfa , by Region USD Million (2022-2027)
  • Table 106. Erythropoietin Epo Drugs Epoetin-beta , by Region USD Million (2022-2027)
  • Table 107. Erythropoietin Epo Drugs Darbepoetin-alfa , by Region USD Million (2022-2027)
  • Table 108. Erythropoietin Epo Drugs Others , by Region USD Million (2022-2027)
  • Table 109. Erythropoietin Epo Drugs: by Application(USD Million)
  • Table 110. Erythropoietin Epo Drugs Cancer , by Region USD Million (2022-2027)
  • Table 111. Erythropoietin Epo Drugs Hematology , by Region USD Million (2022-2027)
  • Table 112. Erythropoietin Epo Drugs Renal diseases , by Region USD Million (2022-2027)
  • Table 113. Erythropoietin Epo Drugs Neurology , by Region USD Million (2022-2027)
  • Table 114. Erythropoietin Epo Drugs: by Drug Class(USD Million)
  • Table 115. Erythropoietin Epo Drugs Biologics , by Region USD Million (2022-2027)
  • Table 116. Erythropoietin Epo Drugs Biosimilars , by Region USD Million (2022-2027)
  • Table 117. South America Erythropoietin Epo Drugs, by Country USD Million (2022-2027)
  • Table 118. South America Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 119. South America Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 120. South America Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 121. Brazil Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 122. Brazil Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 123. Brazil Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 124. Argentina Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 125. Argentina Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 126. Argentina Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 127. Rest of South America Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 128. Rest of South America Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 129. Rest of South America Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 130. Asia Pacific Erythropoietin Epo Drugs, by Country USD Million (2022-2027)
  • Table 131. Asia Pacific Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 132. Asia Pacific Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 133. Asia Pacific Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 134. China Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 135. China Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 136. China Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 137. Japan Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 138. Japan Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 139. Japan Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 140. India Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 141. India Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 142. India Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 143. South Korea Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 144. South Korea Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 145. South Korea Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 146. Australia Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 147. Australia Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 148. Australia Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 149. Rest of Asia-Pacific Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 150. Rest of Asia-Pacific Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 151. Rest of Asia-Pacific Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 152. Europe Erythropoietin Epo Drugs, by Country USD Million (2022-2027)
  • Table 153. Europe Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 154. Europe Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 155. Europe Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 156. Germany Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 157. Germany Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 158. Germany Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 159. France Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 160. France Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 161. France Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 162. Italy Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 163. Italy Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 164. Italy Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 165. United Kingdom Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 166. United Kingdom Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 167. United Kingdom Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 168. Netherlands Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 169. Netherlands Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 170. Netherlands Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 171. Rest of Europe Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 172. Rest of Europe Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 173. Rest of Europe Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 174. MEA Erythropoietin Epo Drugs, by Country USD Million (2022-2027)
  • Table 175. MEA Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 176. MEA Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 177. MEA Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 178. Middle East Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 179. Middle East Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 180. Middle East Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 181. Africa Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 182. Africa Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 183. Africa Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 184. North America Erythropoietin Epo Drugs, by Country USD Million (2022-2027)
  • Table 185. North America Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 186. North America Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 187. North America Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 188. United States Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 189. United States Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 190. United States Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 191. Canada Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 192. Canada Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 193. Canada Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 194. Mexico Erythropoietin Epo Drugs, by Type USD Million (2022-2027)
  • Table 195. Mexico Erythropoietin Epo Drugs, by Application USD Million (2022-2027)
  • Table 196. Mexico Erythropoietin Epo Drugs, by Drug Class USD Million (2022-2027)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Erythropoietin Epo Drugs: by Type USD Million (2016-2021)
  • Figure 5. Global Erythropoietin Epo Drugs: by Application USD Million (2016-2021)
  • Figure 6. Global Erythropoietin Epo Drugs: by Drug Class USD Million (2016-2021)
  • Figure 7. South America Erythropoietin Epo Drugs Share (%), by Country
  • Figure 8. Asia Pacific Erythropoietin Epo Drugs Share (%), by Country
  • Figure 9. Europe Erythropoietin Epo Drugs Share (%), by Country
  • Figure 10. MEA Erythropoietin Epo Drugs Share (%), by Country
  • Figure 11. North America Erythropoietin Epo Drugs Share (%), by Country
  • Figure 12. Global Erythropoietin Epo Drugs share by Players 2021 (%)
  • Figure 13. Global Erythropoietin Epo Drugs share by Players (Top 3) 2021(%)
  • Figure 14. Global Erythropoietin Epo Drugs share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 17. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 18. Celltrion, Inc. (South Korea) Revenue, Net Income and Gross profit
  • Figure 19. Celltrion, Inc. (South Korea) Revenue: by Geography 2021
  • Figure 20. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 21. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2021
  • Figure 22. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Amgen Inc. (United States) Revenue: by Geography 2021
  • Figure 24. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Roche Holding AG (Switzerland) Revenue: by Geography 2021
  • Figure 26. LG Life Sciences Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 27. LG Life Sciences Ltd. (South Korea) Revenue: by Geography 2021
  • Figure 28. Biocon Limited (India) Revenue, Net Income and Gross profit
  • Figure 29. Biocon Limited (India) Revenue: by Geography 2021
  • Figure 30. Intas Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 31. Intas Pharmaceuticals Ltd. (India) Revenue: by Geography 2021
  • Figure 32. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 33. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2021
  • Figure 34. Dr. Reddy's Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 35. Dr. Reddy's Laboratories Ltd. (India) Revenue: by Geography 2021
  • Figure 36. Global Erythropoietin Epo Drugs: by Type USD Million (2022-2027)
  • Figure 37. Global Erythropoietin Epo Drugs: by Application USD Million (2022-2027)
  • Figure 38. Global Erythropoietin Epo Drugs: by Drug Class USD Million (2022-2027)
  • Figure 39. South America Erythropoietin Epo Drugs Share (%), by Country
  • Figure 40. Asia Pacific Erythropoietin Epo Drugs Share (%), by Country
  • Figure 41. Europe Erythropoietin Epo Drugs Share (%), by Country
  • Figure 42. MEA Erythropoietin Epo Drugs Share (%), by Country
  • Figure 43. North America Erythropoietin Epo Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson (United States)
  • Celltrion, Inc. (South Korea)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Amgen Inc. (United States)
  • Roche Holding AG (Switzerland)
  • LG Life Sciences Ltd. (South Korea)
  • Biocon Limited (India)
  • Intas Pharmaceuticals Ltd. (India)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Dr. Reddy's Laboratories Ltd. (India)
Additional players considered in the study are as follows:
3SBio (China) , Boehringer Ingelheim (United States) , BIOSIDUS (Argentina) , Others
Select User Access Type

Key Highlights of Report


Aug 2022 230 Pages 71 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Erythropoietin Epo Drugs Market Quantitative research analysis
Global Erythropoietin Epo Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Erythropoietin Epo Drugs Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Erythropoietin Epo Drugs market is dominated by Indians Players and may generate healthy valuation by 2027.
  • Cases of Cancer, HIV, Kidney Disease, and Anaemia Are On the Rise
  • Rising Public Awareness of the Advantages of EPO Therapeutics
dominated the Erythropoietin Epo Drugs market. This is attributable to growing trend of "Erythropoietin Biosimilars Are Becoming More Commercially Viable"

Know More About Global Erythropoietin Epo Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Implantable Drug Delivery Devices Comprehensive Study by Type (Biodegradable, Non-Biodegradable), Application (Contraception, Ophthalmology, Cardiovascular, Diabetes, Oncology, Autoimmune Diseases, O...
$ 3800
Central Fill Pharmacy Automation System Comprehensive Study by Application (Inpatient Pharmacy, Outpatient Pharmacy, Retail Pharmacy, Others), Services (Consulting, Workflow and process optimization,...
$ 3500
Kyphoplasty Comprehensive Study by Type (Balloon Catheters, Bone Access Devices, Cement Application Products, Bone Cement, Cement Mixing Systems, Instruments), Application (Vertebral Alignment Restor...
$ 3800
Salt Rooms Construction Comprehensive Study by Type (Salt Walls, Bricks & Tiles, Salt Booths & Capsules, Salt Beds & Tables, Halogenerator, Salt Binder, Salt Lamp, Others), Application (Spa and Welln...
$ 3800
Pet Animal Health Product Comprehensive Study by Type (Vaccines, Pharmaceuticals, Calcium Supplement, Others), End Users (Commercials, Household, Pet hospital, Others), Distribution Channels (Online,...
$ 3800
Papillomavirus Hpv Testing Comprehensive Study by Type (HPV Testing, Pap Test), Application (Cervical Cancer Screening, Vaginal Cancer Screening, Molecular Diagnostics, Research Use), End User (Labo...
$ 3800